Welcome to our dedicated page for SANUWAVE Health SEC filings (Ticker: SNWV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SANUWAVE Health, Inc. filings document a Nevada medical-device company focused on directed-energy systems for advanced wound care and regenerative medicine. Form 8-K reports record results of operations, preliminary financial information, investor presentation materials and material-event disclosures related to the company’s wound care business.
Regulatory filings also cover governance and capital-market disclosure subjects, including annual meeting proxy proposals, director elections, auditor ratification, stockholder advisory votes on executive compensation, officer appointments, compensatory arrangements and separation agreements. Additional filings document accounting matters such as non-reliance on previously issued financial statements connected to historical sales and use tax liabilities.
SANUWAVE Health, Inc. has a significant shareholder reported on a Schedule 13G/A. Solas Capital Management, LLC, a Delaware-based registered investment adviser, and its portfolio manager Frederick Tucker Golden report beneficial ownership of 610,968 shares of common stock. This represents 7.1% of the 8,598,976 common shares outstanding as of May 8, 2026, as represented by the company. Solas and Golden report no sole voting or dispositive power, but shared voting and shared dispositive power over 610,968 shares, which are held by two private funds and another sub-advised fund for the benefit of their investors. The funds themselves expressly disclaim beneficial ownership of the reported securities pursuant to Rule 13d-4.
Sanuwave Health reported Q2 2026 results with softer revenue and earnings. Revenue was $9.7 million, down 3% from $10.1 million, and gross margin was 76.2% versus 78.1% a year earlier. Ultramist system sales declined to 82 units from 116, while Ultramist applicator revenue grew 13% to $7.3 million, accounting for roughly three-quarters of total revenue.
The business shifted from profit to loss: Q2 operating loss was $0.3 million versus $1.4 million income, and net loss was $0.7 million versus $0.6 million income in Q2 2025. Adjusted EBITDA fell to $1.2 million from $3.2 million. Management highlighted a challenging advanced wound care market, CMS reimbursement changes, and a growing secondary market for used Ultramist systems as pressures on new system sales. In light of Medicare reimbursement developments and a CMS proposed rule for 2027 code 97610, Sanuwave withdrew its 2026 guidance and does not plan to provide new guidance until after CMS issues its final rule, anticipated in the fourth quarter of 2026.
SANUWAVE Health, Inc. reported Q2 2026 revenue of $9.7 million, down 3% from Q2 2025, and a net loss of $0.7 million versus prior-year net income of $0.6 million. For the first six months of 2026, revenue was $19.4 million, essentially flat year over year, while the net loss narrowed to $2.1 million from $5.6 million.
Gross margin remained high at 76% in Q2 2026 but declined modestly due to lower UltraMIST system volumes and pricing and a mix shift toward consumables. Operating expenses increased across general and administrative, selling and marketing, and research and development, driving an operating loss of $0.3 million for the quarter and $1.4 million year-to-date. Below operating income, total other expense improved sharply, helped by a large reduction in interest expense after a 2025 debt refinancing.
Cash and cash equivalents were $9.4 million at June 30, 2026, with $18.7 million outstanding on a secured term loan and $0.7 million drawn on a revolving credit facility; operating activities generated $0.8 million of cash in the first half. The company has accrued $4.5 million for state and local sales taxes, interest, and penalties and is resolving these exposures through voluntary disclosure agreements. Disclosure controls and internal control over financial reporting remained ineffective due to previously identified material weaknesses in accounting resources, revenue recognition and sales tax processes, and information technology controls, with remediation efforts ongoing.
Opaleye Management Inc., Opaleye, L.P., and James Silverman report beneficial ownership of SANUWAVE Health, Inc. common stock on an amended Schedule 13G. The reporting persons are deemed to beneficially own 309,948 shares of common stock, representing 3.60% of the class, based on 8,598,976 shares outstanding as of May 8, 2026. All 309,948 shares are held directly by Opaleye, L.P., with shared voting and dispositive power and no sole voting or dispositive power reported. The filing states this reflects ownership of 5 percent or less of the class and includes a joint filing agreement among the reporting persons.
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership of common stock of SANUWAVE HEALTH INC. BlackRock reported beneficial ownership of 132,058 shares of common stock, representing 1.5% of the class as of this amendment.
BlackRock reported sole voting power and sole dispositive power over all 132,058 shares, with no shared voting or dispositive power. The filing notes that various persons may have rights to dividends or sale proceeds through BlackRock-managed accounts, but no such person holds more than five percent of SANUWAVE HEALTH INC’s outstanding common shares.
Sanuwave Health, Inc. reported preliminary, unaudited revenue for the quarter ended June 30, 2026 in the range of $9.6–$9.8 million, above the high end of its revised guidance of $8.5–$9.5 million. Preliminary Q2 2026 revenue is approximately 3–5% lower than the $10.1 million reported in the second quarter of 2025.
Management highlighted headwinds in capital equipment sales from customer financial stress and a growing secondary market for used Ultramist systems, while noting record revenues and unit sales for consumable applicators. The revenue figures are based on initial analysis and may change after the completion of quarter-end closing and review procedures.
SANUWAVE Health director Jeffrey Blizard received a grant of 5,524 stock options on June 30, 2026. The options have an exercise price of $10.0000 per share, are exercisable into 5,524 shares of common stock, and were fully vested at the grant date. Following this compensation-related award, Blizard holds 5,524 derivative securities with an expiration date of June 30, 2031, and no open-market purchases or sales were reported in this filing.
SANUWAVE Health director Ian D. Miller received a grant of stock options, giving him the right to acquire 6,215 shares of Common Stock. The options have an exercise price of $10.00 per share, were fully vested on the grant date, and expire on June 30, 2031. Following this award, he holds 6,215 derivative securities directly.
SANUWAVE Health, Inc. director Gregory Matthew Bazar received a grant of stock options as part of his compensation. He was awarded 5,524 options to buy Common Stock at an exercise price of $10.00 per share. The options were fully vested on the grant date and expire on June 30, 2031. Following this grant, he holds stock options for 5,524 underlying shares directly, with no shares reported as bought or sold in the market.
SANUWAVE Health director Tyler James received a new stock option grant. He was awarded options covering 5,524 shares of Common Stock at an exercise price of $10.0000 per share. The options were fully vested on the grant date and expire on June 30, 2031. Following this grant, he holds 5,524 derivative securities directly.